Streetbeat News

ASND

Ascendis Pharma A/S

Industry

Biotechnology

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Open

127.40

Mkt cap

7.1B

Volume

382K

High

127.99

P/E Ratio

-13.18

52-wk high

161.00

Low

124.11

Div yield

N/A

52-wk low

86.55

Wedbush analyst Andreas Argyrides maintains an Outperform rating on Ascendis Pharma (NASDAQ:ASND) and raises the price target from $207 to $225.

Portfolio Pulse from Benzinga Newsdesk

February 08, 2024 | 1:27 pm

Ascendis Pharma (NASDAQ:ASND) reported a Q4 2023 GAAP EPS of $(1.66), missing the $(1.59) estimate, with sales reaching $148.22M, a 534.24% increase from $23.37M YoY.

Portfolio Pulse from Benzinga Newsdesk

February 07, 2024 | 10:02 pm

Numerous companies are scheduled to report their earnings on February 7, 2024, covering a wide range of industries from technology to healthcare. Notable mentions include Madison Square Garden, Scotts Miracle Gro, TotalEnergies, Equinor, Euronet Worldwide, Flex LNG, Alibaba Group Holding, and many others. The earnings reports are expected to provide insights into the companies' financial health and market performance.

Portfolio Pulse from Benzinga Insights

February 07, 2024 | 10:13 am

Ascendis Pharma (NASDAQ:ASND) is scheduled to release its quarterly earnings report on February 7, 2024, with an estimated EPS of $-2.15. Historical data shows mixed reactions to past earnings, with the last quarter missing estimates and causing a 1.47% drop in share price. Over the last year, ASND shares have increased by 24.54%, indicating positive long-term shareholder sentiment. Investors will be keenly watching for not only the earnings outcome but also the company's future guidance.

Portfolio Pulse from Benzinga Insights

February 06, 2024 | 5:01 pm

Cantor Fitzgerald analyst Li Watsek maintains an Overweight rating on Ascendis Pharma (ASND) and raises the price target from $152 to $173.

Portfolio Pulse from Benzinga Newsdesk

February 06, 2024 | 2:49 pm

Over the past 5 years, Ascendis Pharma (NASDAQ:ASND) has outperformed the market with an annualized return of 15.86%, turning a $100 investment into $206.62. The company now has a market capitalization of $8.02 billion.

Portfolio Pulse from Benzinga Insights

February 02, 2024 | 7:30 pm

Ascendis Pharma has partnered with Frazier Life Sciences to form and launch a new company, Eyconis, Inc. This strategic move aims to leverage Ascendis Pharma's expertise in the development of innovative therapies.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 1:43 pm

Er-Kim has entered into an exclusive distribution agreement with Ascendis Pharma A/S (NASDAQ:ASND) to commercialize three endocrinology disease treatments in Central & Eastern Europe and Turkey. The treatments include SKYTROFA for growth hormone deficiency, YORVIPATH for chronic hypoparathyroidism, and TransCon CNP for achondroplasia. Ascendis Pharma aims to broaden patient access to these treatments in collaboration with Er-Kim, which has expertise in rare diseases and endocrinology in the region.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 3:58 am

Vector Pharma FZCO has entered into an exclusive distribution agreement with Ascendis Pharma for the commercialization of Skytrofa and Yorvipath in the Middle East, covering Saudi Arabia, United Arab Emirates, Kuwait, Oman, Qatar, and Bahrain.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:21 pm

Ascendis Pharma A/S (NASDAQ:ASND) introduced Vision 2030 and selected 2024 corporate milestones. The company expects ~€400M in cash and securities as of December 31, 2023, and forecasts 2024 SKYTROFA revenue of €320M-€340M. SKYTROFA is approved in the U.S. and EU for growth hormone deficiency. Ascendis plans to submit applications for other products in 2024 and aims to achieve blockbuster status for multiple products. The company will present at the J.P. Morgan Healthcare Conference and expects to be operating cash flow breakeven by end of 2024.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:16 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.